Development of a dual inhibitor of pan-RAF and VEGFR2 for the treatment of metastatic colorectal cancer with mutant K-RAS

被引：0
|
作者：
Hong, Sungpyo
Choi, Young-Il
Choi, Jihye
Kim, Wonyoung
Kwon, Ho-Seok
Park, Yong Bin
Ki, Min-Hyo
Shin, Hee Jong
Lee, Michael
Ahn, Soon Kil
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3782
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3782
引用
收藏
页数：4
相关论文
共 50 条
  • [31] K-Ras mutant Adenocarcinoma of the Lung (metastatic NSCLC): Parameters of Treatment relevant to Prognosis
    Grohe, C.
    Kurz, S.
    Lueders, H.
    Keilholz, U.
    Frost, N.
    Josten, M.
    PNEUMOLOGIE, 2023, 77 : S82 - S82
  • [32] Reliability of K-ras mutational analysis on cytological samples from metastatic colorectal cancer
    Bozzeti, C.
    Negri, F. V.
    Naldi, N.
    Nizzoli, R.
    Bortesi, B.
    Zobi, V.
    Azzoni, C.
    Silini, E. M.
    Ardizzoni, A.
    PATHOLOGICA, 2011, 103 (03) : 77 - 78
  • [33] Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells
    Lebedeva, I. V.
    Su, Z-Z
    Emdad, L.
    Kolomeyer, A.
    Sarkar, D.
    Kitada, S.
    Waxman, S.
    Reed, J. C.
    Fisher, P. B.
    ONCOGENE, 2007, 26 (05) : 733 - 744
  • [34] Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells
    I V Lebedeva
    Z-Z Su
    L Emdad
    A Kolomeyer
    D Sarkar
    S Kitada
    S Waxman
    J C Reed
    P B Fisher
    Oncogene, 2007, 26 : 733 - 744
  • [35] The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
    Mao, Wei-feng
    Shao, Min-hua
    Gao, Pin-ting
    Ma, Ji
    Li, Hui-juan
    Li, Gai-ling
    Han, Bao-hui
    Yuan, Chong-gang
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (10) : 1311 - 1318
  • [36] The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
    Wei-feng Mao
    Min-hua Shao
    Pin-ting Gao
    Ji Ma
    Hui-juan Li
    Gai-ling Li
    Bao-hui Han
    Chong-gang Yuan
    Acta Pharmacologica Sinica, 2012, 33 : 1311 - 1318
  • [37] Analysis of mutant K-ras in multiple sites of normal appearing mucosa of colorectal cancer patients
    Minamoto, T
    Yamashita, N
    Ochiai, A
    Mai, M
    Sugimura, T
    Ronai, Z
    Esumi, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (05) : 911 - 915
  • [38] Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR
    Nollau, P
    Moser, C
    Weinland, G
    Wagener, C
    INTERNATIONAL JOURNAL OF CANCER, 1996, 66 (03) : 332 - 336
  • [39] Antitumor activity of YAP1 inhibitor in K-Ras mutant lung cancer cells
    Shimomura, Iwao
    Yamamoto, Yusuke
    Tada, Yuji
    Tatsumi, Koichiro
    Ochiya, Takahiro
    CANCER SCIENCE, 2018, 109 : 1182 - 1182
  • [40] RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
    Garcia-Gomez, Antonio
    Ocio, Enrique M.
    Pandiella, Atanasio
    San Miguel, Jesus F.
    Garayoa, Mercedes
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 200 - 205
12345